LAUSR

5-FU: 5-fluorouracil 2% solution App: application BCC: basal cell carcinoma COVID-19: coronavirus disease 2019 IMI: imiquimod 5% cream KCs: keratinocyte carcinomas SCC: squamous cell carcinoma TRET: tretinoin 0.1% cream INTRODUCTION The recent coronavirus disease 19 (COVID-19) crisis has resulted in an economic downturn and the implementation of policies such as social distancing and shelter-in-place. In light of these events, the US government has passed the Coronavirus Preparedness and Response Supplemental Appropriations Act. This act relaxed Health Insurance Portability and Accountability Act regulations and instituted new avenues of revenue for telehealth, including (1) real-time audio-video technology communication; (2) store-and-forward technology, which collects data to be later transmitted via virtual check-ins, email, or other digital applications; and (3) verbal/audio-only communication without images or prerecorded videos. Moreover, latest polls have found that around two-thirds of patients are willing to try telehealth because of the pandemic. These factors have allowed physicians to provide virtual care for patients who are receptive to such technology while adhering to newly instituted policies. The various treatment options for keratinocyte carcinomas (KCs)—surgery, radiation, lasers, curettage and electrodesiccation, photodynamic therapy, intralesional chemotherapy, and cryotherapy— require in-person office visits for implementation.